According to results from the PROpel phase III trial, Lynparza (olaparib) in combination with abiraterone had a significant positive effect on radiographic progression-free survival versus standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.
The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.
